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Rejuvenation is an old dream of an ageing humankind. In
our societies – with their confidence in scientific and tech-
nological fixes and high demands on individual appearance
and performance – the wrinkles and frailties of advanced
age have become an almost unbearable nuisance.
Blood and other body materials, particularly from young,
strong and/or innocent beings, have long been a popular
source of revitalising remedies, both in fiction and in real
life. Vampire stories come to mind, a favourite teenage
genre. In a novel on a preservationist suffering from heart
failure the recently deceased Swiss writer Markus Werner
invokes a story of a sick knight who can only be rescued by
a virgin voluntarily donating her heart [1].
In biomedical research, a lot of efforts are going into de-
veloping scientifically sound, carefully scrutinised organ
repair and replacement therapies. At times, however, the
compelling idea of using “young” material to refresh an
ageing organism seems to sweep away scientific rigor.
“Fresh cells”, originally from sheep fetuses or placentas,
have been used for cures that are still offered in some spas
and clinics today. Their efficacy, however, seems question-
able to the point that the Swiss Federal Office of Public
Health has taken active steps to curtail their use [2]. Cord
blood is another widespread source of hope and hype, and
stem cell therapies of all sorts have become a blossoming
global market.
Another hot new approach is young human plasma. It has
been known for some time that an old mouse sewn to a
young mouse – a technique from the 19th century called
parabiosis – seems to benefit from the young mouse’s
blood [3]. In spite of its promising results this set-up must
seem somewhat impractical even for the most daring pro-
ponents of anti-ageing medicine. In 2014, a study sugges-
ted that the injection of young blood plasma into elderly
mice may have also beneficial effects, reversing effects of
brain ageing and improving learning and memory [4]. So
far, no significant impact on lifespan has been found [5].
A trial using human plasma for rejuvenation is currently
underway, prompting a number of ethical issues some of
which were recently pinpointed in Science [6]. A major
concern relates to the poor trial design that invites parti-
cipation from anyone who is aged 35 years and older and
willing to pay a charge of 8000 US dollars, but includes
no placebo arm. There is little clinical evidence to start
out with, and because of the way the study is set up it
cannot be expected to contribute much to the status quo.
Apparently a commercial ethics board has reviewed the
study, yet questions remain about the risk-benefit ratio and
the high charge. Additional issues could be raised, such
as: How will incidental findings, which are likely given
the high number of laboratory tests, be dealt with? Were
blood donors informed that their plasma might be used
for non-medical purposes? Furthermore, there are concerns
about possible long-term risks, with worries that rejuvenat-
ing cells in old organisms might lead to an increase in can-
cer [7].
But let us assume that plasma for rejuvenation developed
into a successful therapy, with robust evidence of its clin-
ical effectiveness. Who should be eligible for this therapy?
Alleviating symptoms of patients with Alzheimer’s disease
or brain injuries is one matter, but boosting the perform-
ance of healthy people is quite another.
There would probably be a high demand for such an en-
hancement, if it was indeed safe, effective and reasonably
priced. But at least as long as live donors are needed, hu-
man plasma is not a commodity like any other. Before con-
senting, donors would have to be informed about the in-
tended commercial use in healthy people. This could be
expected to reduce the number of volunteers willing to give
blood under these conditions. Great care would need to be
taken to avoid negative implications for the blood supply
for medical purposes. And clearly, assuming blood will re-
main a scarce resource, use should be prioritised according
to medical need [8]. Enhancement would have to be last in
line.
Thus the availability of young plasma for anti-ageing might
well be limited. In this situation, live directed donation
might become attractive – children or young adults more
or less altruistically donating for their parents or grandpar-
ents. An alternative would be tapping into the global (and
largely illegal) market for organs and other body parts and
pay poor young people in developing countries for their
blood.
Both scenarios have ethical question marks. In the 1970s,
when parabiosis studies were quite popular, an influential
ethics paper appeared, questioning our duty to maintain an-
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other human by presenting the following thought experi-
ment [9]. You wake up in the morning and find yourself
back to back in bed with a famous violinist suffering from
terminal kidney failure who is plugged into your circulat-
ory system. The Society of Music Lovers has kidnapped
you as you are the only one who has the right blood type to
save him by cleaning his blood through your own kidneys.
The peculiar assumptions about the medical situation set
aside, this case was used to discuss the personal obligations
we have to keep others alive. The author, Judith Thompson,
arguing back then in the context of the right to abortion,
concluded there was no such duty.
There is something peculiar about the old literally feeding
on the young. In public discourse, for instance regarding re-
tirement pensions, we usually take care not to overburden
the young generation. Maybe the question comes back to
what Aristotele had already told his pupils: it is about the
right measure. We will all age and die, and many of us
would like to postpone or even abolish both. But our at-
tempts to stay fit as long as possible should not impose un-
due burdens on the next generation. And it would be wise
to accept rather than vainly revolt against human frailty and
mortality. At the end of the day, the end of oneself is not
the end of the world.
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